Hideo Shigematsu
Overview
Explore the profile of Hideo Shigematsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shigematsu H, Fujimoto M, Suzuki K, Ikejiri H, Amioka A, Hiraoka E, et al.
World J Surg Oncol
. 2025 Feb;
23(1):43.
PMID: 39910416
Background: Radiofrequency ablation (RFA) is considered a promising alternative to surgical excision for patients with small, unifocal early-stage breast cancer. A significant concern with the application of RFA in patients...
2.
Shigematsu H, Fukui K, Kanou A, Yokoyama E, Tanaka M, Fujimoto M, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1860-1869.
PMID: 39363123
Background: Tumor-infiltrating lymphocytes-ultrasonography (TILs-US) score is used to predict lymphocyte-predominant breast cancer (LPBC) in surgical specimens. We aimed to compare diagnostic performance of TILs-US score for predicting pathological complete response...
3.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(2):253-262.
PMID: 38922548
Purpose: This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with hormone receptor-positive and human epidermal growth factor...
4.
Shigematsu H, Fukui K, Kanou A, Fujimoto M, Suzuki K, Ikejiri H, et al.
Jpn J Clin Oncol
. 2024 Jun;
54(9):967-974.
PMID: 38864243
Background: The tumor-infiltrating lymphocytes-ultrasonography score is a calculation system for predicting lymphocyte-predominant breast cancers in surgical specimens. A nomogram based on the tumor-infiltrating lymphocytes-ultrasonography score was developed to predict the...
5.
Shigematsu H, Fujimoto M, Kobayashi Y, Yasui D, Komoto D, Matsuura N, et al.
J Magn Reson Imaging
. 2024 May;
61(2):944-955.
PMID: 38809133
Background: Peritumoral edema (PE) identified on T2-weighted breast MRI is a factor for poor prognosis in breast cancer. Purpose: To assess the prognostic value of residual PE (rPE) in patients...
6.
Shigematsu H, Kimura Y, Itagaki T, Yasui D
Medicine (Baltimore)
. 2023 Apr;
102(16):e33580.
PMID: 37083796
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of weekly paclitaxel-based chemotherapy for breast cancer, that can persist for years. Cryotherapy therapy is effective for preventing early CIPN, but...
7.
Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, et al.
Discov Oncol
. 2022 Apr;
13(1):27.
PMID: 35438346
Purpose: FOXP3 + and CD8 + are recognized markers of tumor-infiltrating lymphocytes (TILs) for breast cancer. FOXP3 + TILs are composed of effector Tregs (eTregs) and other subpopulations that are...
8.
Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439165
We conducted the Neo-LaTH study in which patients were randomized to different lengths of neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus the anti-HER2 therapy,...
9.
Kimizu T, Takahashi Y, Oboshi T, Horino A, Omatsu H, Koike T, et al.
Epilepsy Behav
. 2020 May;
109:107116.
PMID: 32388139
Purpose: We investigated the efficacy of methylprednisolone pulse therapy (MP) and responder characteristics in patients with refractory epilepsy. Methods: We reviewed medical records of our center to identify patients with...
10.
Yoshiyama T, Shigematsu H, Yasui D, Yamamoto H, Zaitsu J, Saitou A, et al.
Gan To Kagaku Ryoho
. 2020 May;
47(2):253-257.
PMID: 32381958
The expression of basal marker could be a significant factor for poor prognosis in early stage breast cancer. We evaluated the prognostic value of basal marker in each breast cancer...